Aurora Cannabis (TSX:ACB) About to Get Transformed

Here’s why investors in Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) should expect significant transformative news from the marijuana company soon.

| More on:

Marijuana producer and aggressive growth stock Aurora Cannabis (TSX:ACB)(NYSE:ACB) has been in the news lately over its recent connected actions towards strategic partnerships since engaging a professional investment manager, its latest lodging of a $750 million shelf prospectus, and the latest personnel hire, which indicate a serious commitment to business transformation.

The company had lagged behind in forming strategic partnerships with the major players in the alcohol, tobacco, or pharmaceuticals sectors and any other related industries after the rumoured Coca Cola deal did not materialize. Canopy Growth received a $5 billion investment from Constellation Brands, Cronos Group received a $2.4 billion injection from Altria Group, while Tilray and HEXO each signed on strategic partners.

Aurora is now on a serious drive to quickly address the partnership issue. The company signed on multi-billion-dollar hedge fund manager Nelson Peltz as a strategic advisor in March. The connected deal maker could be very instrumental in negotiating accretive partnerships for the company, and a new hire has been availed who will assist him.

Enter the shrewd investment banker

The company has just hired a former investment banker on a full-time basis.

On Thursday, April 4, the company appointed a former managing director of BMO Capital Markets, Mr Carey Squires, as executive vice president, Corporate Development and Strategy in a bid to support strategic initiatives.

The new position will report directly to the executive chair and will “focus on global growth and partnership strategies” and investor development.

Interestingly, the new hire had been a trusted advisor to the company on a several other strategic deals and he comes with deep global investment banking experience. His new employer may greatly benefit from his networks of strategic contacts as it goes on another aggressive growth spate anchored on global partnerships.

I am just wondering how the investment banker’s working week will be like as a full-time employee of a cannabis firm, tasked with “sourcing potential accretive opportunities in the global cannabis industry and negotiating favourable business transactions,” but the new role may generate a significant number of new strategic alliances for the firm if successfully executed.

A brilliant low-cost expansion strategy replay?

Most impressive and unique is the company’s propensity to hire and internalize the best people and teams for its aggressive growth endeavours.

During the productive facility build-out stage when every licensed producer was making frantic efforts to increase productive capacity, the company decided to acquire a global greenhouse design firm Larssen to create its ALPS subsidiary. The transaction saved a lot of cash for engineering consultancy and project management fees and was very strategically accretive, too.

As investor focus has shifted to strategic alliances and partnerships now, the company has hired and internalized the best brains for investment deal negotiation and structuring, and may save on paying hefty cash finder’s fees and consultancy fees.

The company may pay the new executive much less cash than what outside consultants will have charged and offer him more in stock-based compensation while tapping into his rich networks in the investment industry. The result may be very similar to the Larssen acquisition.

Larssen engineers were critical in Green Organic Dutchman and Denmark strategic deals, and the company is on track to becoming a producer of 570,000 kilograms of marijuana per annum.

I’m curious just how many partnerships the company targets to establish through Peltz and Squires for it to rule the global marijuana industry. This could mean a good number of them, and the deals may significantly transform Aurora into the great marijuana stock investors desire.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »